Skip to main content
Medinice S.A. logo

Medinice S.A. — Investor Relations & Filings

Ticker · ICE ISIN · PLMDNCE00016 LEI · 259400LGO9UDV1Y18Z11 WAR Manufacturing
Open in API
Filings indexed 761 across all filing types
Latest filing 2023-10-13 Director's Dealing
Country PL Poland
Listing WAR ICE

About Medinice S.A.

https://www.medinice.pl/?lang=2

Medinice S.A. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions in the fields of cardiology and cardiac surgery. The company's mission is to create patient-focused technologies that improve the quality of life for individuals with cardiac diseases. Its portfolio consists of advanced medical devices, including Class III devices, which undergo a full research, development, and clinical trial process before market introduction. Key projects include CoolCryo, a cryoablation system; AtriClamp, for left atrial appendage closure; and PacePress, a specialized compression band used after cardiac device implantation procedures.

Recent filings

Filing Released Lang Actions
Powiadomienie o transakcji o której mowa w art. 19 ust. 1 rozporządzenia MAR
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction (Nabycie - Acquisition) involving shares by a person discharging managerial responsibilities (Prezes Zarządu - CEO/President of the Management Board), Sanjeev Choudhary, in the company MEDINICE SPÓŁKA AKCYJNA. This structure and content precisely match the definition of insider trading reports, specifically director's dealings under MAR (Market Abuse Regulation). This corresponds to the 'Director's Dealing' category (DIRS).
2023-10-13 Polish
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce o nabyciu akcji. - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (597 characters) and explicitly mentions receiving a notification regarding transactions in company shares by a member of the Management Board (Prezes Zarządu). It cites Article 19 of the MAR Regulation (EU) No 596/2014, which specifically deals with transactions by persons discharging managerial responsibilities (insider trading/dealing). This directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions the notification is an attachment, the core content is the announcement of the dealing itself, making DIRS a more specific fit than RPA or RNS.
2023-10-13 Polish
Zawiadomienie o zmianie stanu posiadania udziału w ogólnej liczbie głosów w spółce. - Content (PL)
Major Shareholding Notification Classification · 98% confidence The document text is very short (790 characters) and reports a notification received by the company ('Emitent') from a shareholder ('Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.'). The notification concerns a transaction (sale of shares) that resulted in the shareholder's stake falling below the 5% threshold of total voting rights. This directly relates to changes in significant share ownership levels, which corresponds to the Major Shareholding Notification (MRQ) definition. It is not a full report, an earnings release, or a director's dealing, but a notification of a change in a major shareholder's stake.
2023-10-10 Polish
Podpisanie listu intencyjnego dotyczącego nabycia istotnego pakietu udziałów w spółce rozwijającej technologię sztucznej inteligencji w obszarze kardiologii. - Content (PL)
M&A Activity Classification · 99% confidence The document text, written in Polish, describes Medinice S.A. signing a letter of intent (list intencyjny) on September 27, 2023, regarding the acquisition of a significant stake in a company developing AI technology in cardiology. It details the target company's technology, the strategic rationale for the investment (expanding the portfolio, identifying synergies), the estimated transaction value (approx. 1 million PLN), and the next steps (due diligence). This content clearly relates to a potential merger or acquisition activity. Based on the definitions, this falls under 'M&A Activity' (Code: TAR). The document is a substantive report detailing the proposed transaction, not merely an announcement that a report is forthcoming.
2023-09-28 Polish
Zakończenie pierwszego z dwóch etapów fazy prototypowania i zakończenie współpracy z podwykonawcą w projekcie EP Bioptom - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a formal announcement from the Management Board ('Zarząd') of Medinice S.A. regarding the completion of the first stage of prototyping for the EP Bioptom project and the termination of cooperation with a subcontractor. It details the status of a research and development (R&D) project co-financed by NCBiR (National Centre for Research and Development). This content relates to the company's operational progress, R&D activities, and potentially future product development, but it is not a standard financial report (10-K, IR, ER) or a management change (MANG). It is a specific update on a significant project. Given the options, this type of operational/project update that is not a standard financial filing or a specific legal/director event fits best under the general 'Regulatory Filings' (RNS) category, as it is a required disclosure about a material event, or potentially a general 'LTR' if it involved a dispute, but here it seems like a planned termination/completion of a phase. Since it is a specific, material operational update that doesn't fit the other specific categories (like DIV, CAP, MANG, ER), RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback, as it is a formal disclosure of a material event. Revisiting the definitions, this is a disclosure of a material event concerning R&D progress and subcontractor status. It is not a standard financial report, management change, or dividend announcement. It is a specific operational update. Given the lack of a specific 'R&D Update' category, RNS serves as the best general regulatory disclosure category.
2023-09-25 Polish
Raport biegłego rewidenta - skonsolidowany
Audit Report / Information Classification · 99% confidence The document is explicitly titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Report on the Review of the Interim Condensed Consolidated Financial Statements) for the period ending June 30, 2023. This document contains the auditor's conclusion based on a review of interim financial statements, which aligns perfectly with the definition of an Audit Report / Information (AR). It is not a full Annual Report (10-K) nor is it merely an announcement of a report (RPA), as it contains the substantive review conclusion itself. H1 2023
2023-08-24 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.